https://www.selleckchem.com/pr....oducts/baxdrostat.ht
Leading reasons FAST-MAG patients were ineligible for post-arrival acute trials were NIHSS too low (23.4%), intracranial hemorrhage (17.9%), IV tPA used in standard management (9.0%), NIHSS too high (7.1%), and age too high (5.2%). A prehospital hyperacute stroke trial with wide entry criteria reduced only modestly, by one-fourth, enrollment into concurrently active, post-arrival stroke trials. Simultaneous performance of prehospital and post-arrival acute and secondary prevention stroke trials in research networks is feasible. A pre
Like
Comment
Share
